Head and Neck Cancer Pipeline Assessment, 2022 | Latest FDA, EMA, and PMDA Approvals, Emerging Therapies, Ongoing Clinical Trials | Galectin, Cue Biopharma, CEL-SCI Corporation, PDS Biotech

October 17 21:03 2022
Head and Neck Cancer Pipeline Assessment, 2022 | Latest FDA, EMA, and PMDA Approvals, Emerging Therapies, Ongoing Clinical Trials | Galectin, Cue Biopharma, CEL-SCI Corporation, PDS Biotech
Delveinsight Business Research LLP
As per DelveInsight’s assessment, globally, about 130+ key pharma and biotech companies are working on 150+ pipeline drugs in the Head and Neck Cancer therapeutics landscape based on different Routes of Administration (RoA), Mechanism of Action (MoA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

Head and Neck Cancer Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the  Head and Neck Cancer Market. 

The Head and Neck Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. 

The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Head and Neck Cancer Pipeline Analysis

Head and Neck Cancer Pipeline Analysis

The report provides insights into: 

  • The report provides detailed insights about emerging therapies for the treatment of Head and Neck Cancer and the aggregate therapies developed by major pharma companies.

  • It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Head and Neck Cancer Treatment.

  • It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

  • The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

  • It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Head and Neck Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

DelveInsight’s Report covers around 150+ products under different phases of clinical development like

  • Late-stage products (Phase III)

  • Mid-stage products (Phase II)

  • Early-stage product (Phase I), along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

Learn How the Ongoing Clinical & Commercial Activities will Affect the Head and Neck Cancer Therapeutic Segment:


Head and Neck Cancer Therapeutics Landscape

There are approx. 130+ key companies developing therapies for Head and Neck cancer. Currently, Innate Pharma has its Head and Neck cancer drug candidates in the most advanced stage of clinical development.

Some of the key companies in the Head and Neck cancer (HNC) Market include:

Innate Pharma, GlaxoSmithKline, Debiopharm, MacroGenics, Takeda Oncology, CSPC ZhongQi, PNP Therapeutics, IntraGel Therapeutics, Incyte, Corregene, TyrNovo Ltd., BioNTech SE, Adlai Nortye Biopharma Co., Merck KGaA, Aveta Biomics, Inc., Cellectar Biosciences, Inc., Nanobiotix, ALX Oncology, Nektar Therapeutics, Ikena Oncology, AstraZeneca, Arcus Biosciences, Inc., Roche, Vaccinex, Pfizer, Astex, Eli Lilly and Company, Bayer HealthCare, Kura Oncology, Cue Biopharma, Shanghai Henlius Biotech, Merus N.V., NanoCarrier Co., Ltd., Alkermes, Inc., Rubius Therapeutics, iTeos Belgium SA, Transgene, Boehringer Ingelheim, Immutep S.A.S., Compugen Ltd, Galectin Therapeutics, BioAtla, Inc., Betta Pharmaceuticals Co., Ltd., Jacobio Pharmaceuticals Co., Ltd., CytomX Therapeutics, Advaxis, Inc., Inhibrx, Inc., Celldex Therapeutics, Carisma Therapeutics Inc, Intensity Therapeutics, Inc., I-Mab Biopharma, Quadriga Biosciences, Inc., Checkpoint Therapeutics, Inc., Wellmarker Bio, Genentech, Inc., Pionyr Immunotherapeutics Inc., Cyteir Therapeutics, Inc., Klus Pharma Inc., Bicycle Therapeutics, Palleon Pharmaceuticals, Inc., Rapa Therapeutics, SN BioScience, Memgen, Inc., and others

Head and Neck cancer (HNC) therapies covered in the report include:

  • Monalizumab

  • Niraparib

  • Xevinapant

  • Enoblituzumab

  • PDS0101 

  • LN-145 

  • CUE-101

  • SNS-301 

  • BIBW2992

And many more

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies:


As per DelveInsight, the dynamics of the Head and Neck Cancer therapeutics market are anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also the expected launch of emerging therapies.

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Head and Neck Cancer Current Treatment Patterns

4. Head and Neck Cancer – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Head and Neck Cancer Late Stage Products (Phase III)

7. Head and Neck Cancer Mid-Stage Products (Phase-II)

8. Head and Neck Cancer Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Head and Neck Cancer Discontinued Products

13. Head and Neck Cancer Product Profiles

14. Key Companies in the Head and Neck Cancer Market

15. Key Products in the Head and Neck Cancer Therapeutics Segment

16. Dormant and Discontinued Products

17. Head and Neck Cancer Unmet Needs

18. Head and Neck Cancer Future Perspectives

19. Head and Neck Cancer Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:



About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports By DelveInsight

Head and Neck Cancer (HNC) Market

“Head and Neck Cancer (HNC) Market” research report provides a detailed overview of the historical and forecasted epidemiology as well as the Head and Neck Cancer Market size, share, and trends in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). Additionally, it also covers the latest innovations, breakthroughs, emerging therapies, and key companies operating in the therapeutics market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/